The 93 patients with four first-line and eight second-line drug susceptibility results were divided into two groups on the basis of gender, age, CD4 cell count, and status of anti-tuberculosis treatment to compare the difference in the resistance rates. The gene discussed is CD4; the disease is tuberculosis.